Chronic kidney disease (CKD) is associated with the development of coronary arteries calcifications (CAC) and increased cardiovascular mortality. Previously, the investigators demonstrated that interleukin 8 (IL-8) plays a role in the calcification process, and that blockade of its receptor, CXCR2 reduces cardiovascular calcifications. The investigators hypothesize that leucocytes expressing CXCR2 may contribute to the development and progression of CAC in CKD patients. Identifying CKD patients with a high calcification phenotype and therapeutic targets to prevent cardiovascular calcifications is essential. Advanced CKD patients (stages IV and V) will undergo analysis of CXCR2 expression from neutrophils and monocytes at inclusion by flow cytometry, followed by non-contrast thoracic CT scans at inclusion, 1 year and 3 years to assess calcification scores and progression. Patients will have a pre-inclusion visit for research information and consent. If consent is given, three protocol visits (inclusion, 1 year, 3 years) including clinical exam, laboratory tests and CT evaluations will be performed.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
100
Thoracic CT will be performed at inclusion, 1 year and 3 years to assess coronary calcification and aortic valve calcification scores and progression.
Blood samples will be collected at inclusion, 1 year and 3 years to measure CXCR1 and CXR2 expression on neutrophils and monocytes by flow cytometry.
CHRU Amiens
Amiens, France
variation from baseline of CXCR2 expression
CXCR2 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells) from blood sample.
Time frame: at 3 years
Correlation between CXCR2 expression and calcium score
The coronary calcification score will be determined by Agatston method. CXCR2 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells) from blood sample.
Time frame: at 3 years
CXCR2 expression and the 1-year progression of the calcium score
The coronary calcification score will be determined by Agatston method. CXCR2 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells) from blood sample.
Time frame: at 1 year
Correlation between CXCR1 or CXCR2 expression and calcium score trajectory
The coronary calcification score will be determined by Agatston method. CXCR2 expression and CXCR1 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells and percentage of CXCR1 positive cells) from blood sample.
Time frame: 1 year
Correlation between CXCR2 expression and the calcium score progression in other vascular territories
The coronary calcification score will be determined by Agatston method. CXCR2 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells) from blood sample.
Time frame: at 3 years
Correlation between CXCR1 expression and the calcium score progression in other vascular territories
The coronary calcification score will be determined by Agatston method. CXCR1 expression will be quantified by flow cytometry (percentage of CXCR1-positive cells) from blood sample.
Time frame: at 3 years
Correlation between a CXCR1- or CXCR2-positive leukocyte phenotype and CKD progression
The coronary calcification score will be determined by Agatston method. CXCR2 expression and CXCR1 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells and percentage of CXCR1 positive cells) from blood sample.
Time frame: at 3 years
Correlation between a CXCR1- or CXCR2-positive leukocyte phenotype and the occurrence of cardiovascular complications
CXCR2 expression and CXCR1 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells and percentage of CXCR1 positive cells) from blood sample.
Time frame: at 3 years
Correlation between a CXCR1- or CXCR2-positive leukocyte phenotype and mortality
CXCR2 expression and CXCR1 expression will be quantified by flow cytometry (percentage of CXCR2-positive cells and percentage of CXCR1 positive cells) from blood sample.
Time frame: at 3 years
Correlation between leukocyte phenotype and serum indoxyl sulfate concentration
Time frame: at 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.